Health Canada Approves Celltrion’s Infliximab Biosimilar for Treatment of Rheumatoid Arthritis

Goodwin
Contact

Goodwin

Celltrion Healthcare Canada Limited announced yesterday that Health Canada granted a notice of compliance for Remsima SC®, an infliximab biosimilar of J& J’s Remicade®, for the treatment of adult patients with rheumatoid arthritis.

Celltrion Senior Vice President Jovan Antunovic said the company is “delighted to bring the first subcutaneous form of infliximab to patients, payers and clinicians in Canada.”  The press release indicates that the company expects a self-administered infliximab product will make treatment with the drug more convenient for patients.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.